Table 3 Effect of amphotericin B formulations on hepatic and renal parameters.

From: Biomimetically engineered Amphotericin B nano-aggregates circumvent toxicity constraints and treat systemic fungal infection in experimental animals

Amphotericin B Formulations

Dose (mg/kg)

ALTa (IU/L)

ASTa (IU/L)

BUNa (mmol/L)

Creatinine (μmol/L)

Controlb

0

149.8 ± 14.8

18.0 ± 2.0

5.4 ± 2.6

35.5 ± 1.02

AmB-NA3

1

148.3 ± 22.8

19.3 ± 1.9

5.8 ± 0.3

37.5 ± 0.06

5

161.2 ± 8.4

17.3 ± 1.7

6.2 ± 1.9

39.3 ± 1.71

10

154.0 ± 29.4

20.6 ± 7.0

5.5 ± 2.6

42.5 ± 1.00

15

350.0 ± 2.4*

31.8 ± 5.7*

8.8 ± 2.3*

58.5 ± 1.49*

AmB-NA5

1

146.3 ± 2.8

17.3 ± 1.1

5.8 ± 1.3

39.5 ± 1.60

5

162.8 ± 19.2

18.8 ± 4.5

6.0 ± 1.2

36.6 ± 1.52

10

167.1 ± 8.4

19.3 ± 2.7

6.2 ± 1.9

40.0 ± 1.87

15

335.0 ± 8.4*

27.8 ± 2.4*

8.3 ± 1.3*

56.5 ± 1.91*

Fungizone

2

704.0 ± 27.6*

49.0 ± 2.2*

16.2 ± 0.2*

88.7 ± 2.22*

AmBisome

10

205.2 ± 14.3*

24.8 ± 3.8*

5.7 ± 1.0

46.3 ± 3.14

  1. The two commercial formulations of Amphotericin B, Fungizone and AmBisome, were used at dose of 2 and 10 mg/kg, respectively.The new formulations (AmB-NA3 and AmB-NA5) were used in a range of concentrations (1–15 mg/kg). Values are mean ± SD.
  2. *Significant at P < 0.05compared with the results for the respective control mice, Student’s t test.
  3. aALT, alanine aminotransferase; AST, aspartate aminotransferase; BUN, blood urea nitrogen.
  4. bControl mice were given only PBS.
Back to article page